To investigate the effects of lanthanum chloride on binding of LPS to monocyte and CD 14 expression upregulation induced by LPS, human monocytes were analyzed by flow cytometry (FCM). The results indicated that lanthanum chloride could decrease the binding rate of LPS with monocyte significantly. LPS upregulated the expression of CD 14 on monocyte in a dose dependant manner, however, lanthanum ...

BACKGROUND AND OBJECTIVES Phosphate binders such as calcium salts or sevelamer, a cationic polymer, can markedly reduce absorption of oral ciprofloxacin. This randomized, open-label, two-way, crossover study examined the influence of the cation lanthanum on systemic ciprofloxacin exposure after oral administration. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Twelve patients randomly receive...

BACKGROUND The majority of patients with end-stage renal disease on dialysis are hyperphosphataemic. Lanthanum carbonate has been shown to be a highly effective phosphate binder in pre-clinical studies. A 4-week, open-label, dose-titration trial was conducted to assess the ability of lanthanum carbonate to control phosphate levels in patients with chronic renal failure. METHODS This prelimina...

Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate Sir, We recently introduced lanthanum carbonate as an alternative phosphate binder to sevelamer hydrochloride in patients with elevated serum calcium. Lanthanum carbonate has a higher affinity for phosphate than sevelamer HCl, so fewer lanthanum carbonate tablets are required to achieve the sam...

BACKGROUND AND OBJECTIVES Lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS A Phase 2, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of lanthan...

Hyperphosphatemia has been shown to be involved not only in the onset and progression of secondary hyperparathyroidism but also in vascular calcification. In addition, it influences the clinical course of patients with chronic kidney disease. Phosphate (Pi) binder is required in the management of hyperparaphosphatemia, because dietary Pi restriction and Pi removal by hemodialysis alone are insu...

Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in sev...

BACKGROUND Phosphate binders, such as lanthanum carbonate, control elevated serum-phosphate levels in patients with end-stage renal disease (ESRD). Lanthanum carbonate is available in oral powder and tablet form. The aim of this survey was to investigate satisfaction with, preference for, and adherence to lanthanum carbonate oral powder in patients with ESRD. SCOPE Patients from France and Sp...

Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate Sir, We recently introduced lanthanum carbonate as an alternative phosphate binder to sevelamer hydrochloride in patients with elevated serum calcium. Lanthanum carbonate has a higher affinity for phosphate than sevelamer HCl, so fewer lanthanum carbonate tablets are required to achieve the sam...

Optimum conditions for the determination of lanthanum at sub μg level have been developed employing differential pulse polarography. A detection limit of 0.5μg/ml has been achieved. The method successfully been applied for analysis of lanthanum in industrial wastes.